

# Christian Friedrich

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1895189/publications.pdf>

Version: 2024-02-01

19  
papers

407  
citations

933447

10  
h-index

839539

18  
g-index

19  
all docs

19  
docs citations

19  
times ranked

428  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Pharmacokinetics and Pharmacodynamics of Linagliptin. <i>Clinical Pharmacokinetics</i> , 2012, 51, 411-427.	3.5	95
2	Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. <i>European Respiratory Journal</i> , 2021, 58, 2004240.	6.7	58
3	A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of Empagliflozin and Linagliptin After Coadministration in Healthy Male Volunteers. <i>Clinical Therapeutics</i> , 2013, 35, A33-A42.	2.5	56
4	Renal Impairment Has No Clinically Relevant Effect on the Long-Term Exposure of Linagliptin in Patients With Type 2 Diabetes. <i>American Journal of Therapeutics</i> , 2013, 20, 618-621.	0.9	34
5	A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus. <i>BMJ Open</i> , 2013, 3, e001844.	1.9	28
6	Effect of Multiple Oral Doses of Linagliptin on the Steady-State Pharmacokinetics of a Combination Oral Contraceptive in Healthy Female Adults. <i>Clinical Drug Investigation</i> , 2011, 31, 643-653.	2.2	23
7	Absence of Excretion of the Active Moiety of Bisacodyl and Sodium Picosulfate into Human Breast Milk: an Open-label Parallel-group, Multiple-dose Study in Healthy Lactating Women. <i>Drug Metabolism and Pharmacokinetics</i> , 2011, 26, 458-464.	2.2	21
8	Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes Mellitus. <i>Clinical Pharmacokinetics</i> , 2015, 54, 737-750.	3.5	15
9	Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 445-454.	2.4	14
10	First-in-class human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 4552-4564.	2.4	13
11	Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study. <i>Clinical Pharmacokinetics</i> , 2022, 61, 1143-1156.	3.5	11
12	Relative bioavailability of an empagliflozin 25-mg/linagliptin 5-mg fixed-dose combination tablet. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2017, 55, 355-367.	0.6	9
13	Pharmacokinetics of single and multiple oral doses of 5 mg linagliptin in healthy Chinese volunteers. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 50, 889-895.	0.6	8
14	In Vivo Formation of Ethinylestradiol After Intramuscular Administration of Norethisterone Enantate. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 781-789.	2.0	6
15	Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetes. <i>Journal of Diabetes Investigation</i> , 2016, 7, 744-750.	2.4	5
16	Linagliptin fixed-dose combination with metformin is bioequivalent to co-administration of linagliptin and metformin as individual tablets. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 537-48.	0.6	5
17	Effect of food and tablet-dissolution characteristics on the bioavailability of linagliptin fixed-dose combination with metformin: evidence from two randomized trials. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2014, 52, 549-63.	0.6	3
18	Relative bioavailability study of linagliptin/ metformin tablets in healthy Chinese subjects. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2015, 53, 582-593.	0.6	3

#	ARTICLE	IF	CITATIONS
19	Letter to the editor regarding: "Pharmacokinetics of teneligliptin in subjects with renal impairment." Halabi <i>et al</i> ., <i>Clinical Pharmacology in Drug Development</i> 2013;2:246-254. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 417-418.	1.6	0